Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyper-CVAD + ponatinib
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Hyper-CVAD + ponatinib is a combination treatment regimen developed by the M.D. Anderson Cancer Center for the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML) in advanced phases. The regimen combines the Hyper-CVAD chemotherapy backbone—consisting of hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Course A) alternating with high-dose methotrexate and cytarabine (Course B)—with ponatinib, a potent third-generation BCR-ABL1 tyrosine kinase inhibitor. Ponatinib is uniquely effective against the T315I 'gatekeeper' mutation, which confers resistance to earlier TKIs like imatinib and dasatinib. This intensive chemo-immunotherapy approach has demonstrated high rates of complete molecular remission and improved long-term survival in Ph+ ALL patients, potentially reducing the necessity for allogeneic stem cell transplantation.
- Other names
- Hyper-CVAD and ponatinibHyper-CVAD plus ponatinibHyper-CVAD-ponatinib
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)DNADNA polymerase familyDHFR (Dihydrofolate reductase)FGFR (Fibroblast growth factor receptor)GR (Glucocorticoid receptor)PDGFR (PDGFR family)SFK (SRC family kinases)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))VEGFR (VEGFR family)
Beyond the preview
Go deeper on Hyper-CVAD + ponatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hyper-CVAD + ponatinib.